1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- Enhertu Gets EU Panel Backing for Second-Line Gastric Cancer
November 15, 2022
- Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
November 14, 2022
- Takeda to File Dengue Vaccine in Japan Too: CEO
November 14, 2022
- GHIT Fund to Bankroll 790 Million Yen for Filariasis, Onchocerciasis
November 14, 2022
- Kyowa Kirin Files Romiplate for Aplastic Anemia in Japan
November 14, 2022
- Aculys Pharma Kicks Off Japan PIII of Diazepam Nasal Spray
November 11, 2022
- Otsuka, Takara Bio to End Collaboration for Gene Therapy TBI-1301
November 11, 2022
- Aculys Pharma Launches Japan PIII for Narcolepsy Drug Candidate
November 11, 2022
- KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023
November 11, 2022
- Opdivo Nabs Japan Drug Sales Throne for 10th Month: Encise
November 11, 2022
- Japan Ethical Drug Sales Up 4.7% in September: Crecon
November 11, 2022
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…